More on Titrating CBD and THC Whole Plant Extracts

This information and dosing schedule is meant for patients with serious pain or a serious degenerative neurological disorder and do not respond to low doses of whole plant CBD. This should always be discussed with the patient’s physician

1. Start patient off with 5 mg whole plant CBD. This initial CBD extract should have minimal or modest THC in it to assure no significant psychoactivity
2. Increase the whole plant extract by 1 mg/day until 10 mg for MS/neuro/pain and 20 mg for “adjuvant therapy”.
3. Once the CBD dosing is stable, the patient is evaluated. If they have significant remaining pain or spasticity, THC Dosing is begun
4. Patients begin taking their THC by using a THC rich extract. They can easily dose 1 or 2 mg and add it to their CBD “water”.
5. The patients increase the THC dose by 1 mg every other day until they get to a 2:1 CBD:THC ratio.
6. Re-evaluated at that point

Allan Frankel, MD Dr Allan Frankel is one of the few physicians in the US who truly understands Cannabis as a medicine. All treatments suggested have been well studied. Every patient seen by Dr Frankel is given a personally created Treatment Plan created with the patient's specific issues defined. Plant medicine requires "tuning" of the dosing. Dr Frankel works with his patients thru a messaging portal. The use of this portal, allows quick and simple follow up contact with Dr Frankel. Patients are not charged for these messages, as this is how Dr Frankel has learned what he has learned. Follow up appointments in person or by phone/video are also available when needed

You Might Also Enjoy...

Rationing Health Care

With COVID, we have never been more aware of critical shortages of masks, ventilators, hospital beds, etc., all leading to rationing. In this BLOG, Dr Frankel, examines how rationing in our medical care is a much bigger problem than just face masks.

Cannabis May Prevent COVID-19 Infections

Early studies in both Israel and Canada show findings consistent with CBD's effect on COVID-19's ability to take hold in the lungs or the gastrointestinal tract. If the receptors are reduced, the viral infection and pulmonary toxicity should be reduced.